comparemela.com

Latest Breaking News On - Social performance - Page 59 : comparemela.com

Mining Indaba launches the Extractives General Counsel Forum in partnership with Africa Oil Week and Africa Legal

Mining Indaba launches the Extractives General Counsel Forum in partnership with Africa Oil Week and Africa Legal
africanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from africanews.com Daily Mail and Mail on Sunday newspapers.

Africa Oil Week launches the Extractives General Counsel Forum Virtual in partnership with Mining Indaba and Africa Legal

Africa Oil Week launches the Extractives General Counsel Forum Virtual in partnership with Mining Indaba and Africa Legal
africanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from africanews.com Daily Mail and Mail on Sunday newspapers.

Minerva Neurosciences, Inc (NASDAQ:NERV) - Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning

Minerva Neurosciences, Inc (NASDAQ:NERV) - Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Investegate |Minerva Neurosciences, Inc Announcements | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

Message : Required fields Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over one year Pivotal bioequivalence study initiated WALTHAM, Mass., May 12, 2021 (GLOBE NEWSWIRE) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2020. Clinical update On May 11, 2021, the Company announced results of the open-label extension of the phase 3 trial of roluperidone for the treatment of negative symptoms of schizophrenia following the completion of the 40-week open-label extension period. Details are provided in that press release, a

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.